RNS Number : 9425J Renalytix PLC 29 April 2022   Renalytix plc   (" Renalytix " or the " Company ")     Total voting rights   NEW YORK and SALT LAKE CITY , 29 April, 2022 - Renalytix (LSE: RENX) announces that t he Company's total issued share capital consists of 74,760,432 shares of 0.25 pence

RNS Number : 9726I Renalytix PLC 22 April 2022     Renalytix plc ("Renalytix" or the "Company")   Grant of Share Options   New York and SALT LAKE CITY , April  22, 2022   -   Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that its Remuneration Committee has agreed to issue options over a total

Director/PDMR Dealing NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY

NEW YORK and SALT LAKE CITY, April 08, 2022 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 22,814 new ordinary shares of £0.0025 each in the capital of the Company (the "Ordinary Shares") have been issued to

RNS Number : 7218H Renalytix PLC 08 April 2022   Renalytix plc ("Renalytix" or the "Company")   Issue of shares   NEW YORK and SALT LAKE CITY , 8 April, 2022 - Renalytix Plc   (NASDAQ: RNLX) (LSE: RENX)   announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 22,814 new

RNS Number : 7737H Renalytix PLC 08 April 2022   NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ,  CANADA ,  AUSTRALIA , JAPAN , THE REPUBLIC OF SOUTH AFRICA , NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW.

LONDON and SALT LAKE CITY, March 31, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today

RNS Number : 7325G Renalytix PLC 31 March 2022   NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ,  CANADA ,  AUSTRALIA , JAPAN , THE REPUBLIC OF SOUTH AFRICA , NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR

RNS Number : 6807G Renalytix PLC 31 March 2022       Renalytix plc ("Renalytix" or the "Company")   Half Year Report   LONDON and SALT LAKE CITY , March 31, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE : RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing